Monopar Therapeutics shares are trading higher after the company entered into an agreement with Alexion, AstraZeneca Rare Disease, for an exclusive worldwide license to ALXN-1840 for Wilson disease.
Portfolio Pulse from Benzinga Newsdesk
Monopar Therapeutics shares rise following an agreement with Alexion, AstraZeneca Rare Disease, for an exclusive worldwide license to ALXN-1840, a treatment for Wilson disease.
October 24, 2024 | 1:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Monopar Therapeutics' stock is trading higher due to a new agreement with Alexion, AstraZeneca Rare Disease, granting them an exclusive worldwide license to ALXN-1840 for Wilson disease.
The agreement with Alexion, a reputable player in rare diseases, provides Monopar with a significant opportunity to expand its product offerings and market reach, positively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100